Cervical Nags Effect on Accessory Muscles

December 12, 2024 updated by: Riphah International University

Effects of Cervical Nags on Accessory Muscles in Patients With Copd

The aim of this work is to record changes on accessory muscles especially sternocleidomastoid and scalene after applying cervical NAGs in COPD patients.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

Natural gliding movements in the spine, known as apophyseal glides, occur during breathing. These movements are believed to be important for maintaining good posture and flexibility in the spine. In COPD patients, the muscles that support the spine, like the scalene and SCM, can become tight and strained due to labored breathing. This tightness can lead to neck and shoulder pain.

While studies suggest that natural apophyseal glides improve spinal mobility, accessory muscle flexibility and reduce pain, there is room for further research on COPD patients, especially in Pakistan.

Study Type

Interventional

Enrollment (Estimated)

36

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Pakistan
    • Federal
      • Islamabad, Federal, Pakistan, 04485
        • Recruiting
        • Pakistan Institute of Medical Sciences
        • Sub-Investigator:
          • Asmar Fatima, MS-OMPT
        • Contact:
        • Contact:
        • Principal Investigator:
          • Ghaniya Khan, MSOMPT*

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Registered with history of moderate (II) to severe (III) grade COPD (for a minimum of 1 year) will be included in the study.
  • Patients who are clinically stable.

Exclusion Criteria:

  • Patients who have any pre-existing cervical spine disease.
  • Patients who have any cardiac disease.
  • Other respiratory co-morbidities
  • Patients who have severe dizziness or coughing

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Traditional Physical Therapy
Cervical stretches and inspiratory muscle training
Other: Traditional Physical Therapy

Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week

Total of 9 sessions were given each consisting of 40 mins.
Experimental: Mulligan Glides
Mulligan Natural Apophyseal Glides along with cervical stretches and inspiratory muscle training
Other: Mulligan Glides

Natural Apophyseal Glides of Cervical spine are given 3 repetitions x 3-6 sets, 3 days/week.

Diaphragmatic, Pursed Lip breathing and Targeted cervical muscle stretches 10 repetitions x 1 set, 3 days/week

Total of 9 sessions were given each consisting of 40 mins.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Tape Line
Time Frame: 3rd week
Changes from baseline ROM range of motion for cervical flexion,etension, lateral flexion and rotation is measured using tape
3rd week
NPRS
Time Frame: 3rd week
Changes from baseline for pain is measured using NPRS. NPRS stands for Numerical Pain Rating Scale, a common method for assessing pain intensity. It's a simple scale from 0 to 10, where: 0 represents no pain, 1-3 represents mild pain, 4-6 represents moderate pain, 7-10 represents severe pain. Patients are asked to rate their pain by choosing a number on this scale to evaluate and monitor pain levels before and after treatment.
3rd week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dyspnea Index
Time Frame: 3rd week
Changes for baseline for level of Shortness of breath is measured using Dyspnea Index. The dyspnea index, also known as the Modified Medical Research Council (MMRC) scale, measures the severity of breathlessness or dyspnea. It's a 5-point scale: Grade 0: No dyspnea, Grade 1: Dyspnea during strenuous exercise, Grade 2: Dyspnea during moderate exercise, Grade 3: Dyspnea during light exercise or walking on level ground, Grade 4: Dyspnea during daily activities or at rest. This scale helps assess the impact of treatment on copd patients.
3rd week
Tampa Scale of Kinesiophobia
Time Frame: 3rd week

Changes from baseline for level of kinesiophobia is measured using Tampa scale. The most widely used scale for assessing kinesiophobia is the Tampa Scale of Kinesiophobia (TSK). This questionnaire contains 17 items that gauge a person's fear of movement and associated with movement. Each item is rated on a 4-point Likert scale, with a higher score indicating a greater degree of kinesiophobia. It has an excellent reliability of Cronbach Alpha > 0.9 (18).

Scores for each item are added together to get a total score. Scores can range from 17 (low kinesiophobia) to 68 (high kinesiophobia). A cut-off score of 37 is often used to indicate high kinesiophobia in COPD patients.
3rd week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Riphah International University

Investigators

  • Principal Investigator: Asmar Fatima, MSOMPT, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2024

Primary Completion (Estimated)

April 30, 2025

Study Completion (Estimated)

April 30, 2025

Study Registration Dates

First Submitted

June 12, 2024

First Submitted That Met QC Criteria

December 12, 2024

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

December 12, 2024

Last Verified

December 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • REC/MS-PT/01938 Ghaniya Khan

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe